Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073587 · ClinicalTrials.gov registry record
The CARDIO-TTRansform Scintigraphy Sub-study
A clinical trial of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- 150
- Enrollment target
- 5
- Study locations
NCT06073587 is a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT06073587, a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Scintigraphy scan
Study Locations (5)
New York
- Columbia University Irving Medical Center - New York
North Carolina
- Duke University Medical Center - Durham
Ohio
- Cleveland Clinic Main Campus - Cleveland
Oregon
- Oregon Health and Science University - Portland
Other
- Hospital Universitario Puerta de Hierro - Majadahonda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06073587
The ClinicalTrials.gov registry entry for NCT06073587 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 1 intervention - of which Scintigraphy scan is the first listed.
NCT06073587 reports 5 study locations spanning 5 distinct geographic areas - top geographies include New York, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT06073587 about?
NCT06073587 is a clinical study titled "The CARDIO-TTRansform Scintigraphy Sub-study". The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perug...
What is the current status of trial NCT06073587?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2023-04-04. Estimated completion is 2026-03.
What conditions does trial NCT06073587 study?
This clinical trial studies the following conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT06073587?
The interventions under investigation include: Scintigraphy scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06073587?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073587 being conducted?
This trial has 5 study locations across New York, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
ACTIVE NOT RECRUITING · Phase 3
-
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.